Investing.com - Belite Bio ADR (NASDAQ: BLTE) reported fourth quarter EPS of $-0.25, $0.05 better than the analyst estimate of $-0.30. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
Belite Bio ADR's stock price closed at $44.60. It is up 0.97% in the last 3 months and up 43.87% in the last 12 months.
Belite Bio ADR saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Belite Bio ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Belite Bio ADR's Financial Health score is "excellent performance".
Check out Belite Bio ADR's recent earnings performance, and Belite Bio ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar